What is the evidence level for Semaglutide?

Semaglutide is rated Level A. Its current research status is FDA Approved.

What is Semaglutide best known for?

Obesity, type 2 diabetes, cardiovascular risk reduction in overweight patients

Where can I read the full Semaglutide evidence review?

The full evidence review is available at https://examinepeptides.com/library/semaglutide.

Weight Loss & Metabolic / legal status / Last reviewed 2026-06-01

Semaglutide Legal Status: Approval, Research Use, and Regulatory Notes

FDA-approved for type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), cardiovascular risk reduction in adults with established CVD and obesity/overweight, and higher-dose Wegovy HD 7.2mg for weight loss and long-term weight maintenance (March 19, 2026). Prescription required.

Read the full Semaglutide guide Browse answer pages

Direct Answer

Semaglutide remains the best-validated GLP-1-only agent: FDA-approved for diabetes, obesity, cardiovascular risk reduction, and now higher-dose Wegovy HD 7.2mg. Tirzepatide beats it on weight loss in direct obesity trials, but semaglutide still has the deepest cardiovascular outcomes record and the broadest GLP-1 evidence base.

Evidence grade: Level A
Research status: FDA Approved
Category: Weight Loss & Metabolic
Best for: Obesity, type 2 diabetes, cardiovascular risk reduction in overweight patients

Legal and Regulatory Status

Approval Stage

Semaglutide is listed as FDA Approved. Approved uses, if any, are indication-specific and do not automatically apply to other claims.

Compliance Notes

Boxed warning: thyroid C-cell tumors in rodents
Contraindicated with personal/family history of medullary thyroid carcinoma
Risk of pancreatitis
May worsen diabetic retinopathy
Not for use with insulin or other GLP-1 agonists
Gallbladder events reported

Evidence Page

For the complete evidence review, see the main Semaglutide guide linked below.

Evidence Snapshot

Evidence grade	Level A
Research status	FDA Approved
Best supported outcomes	Weight Loss (Level A), Blood Sugar Control (Level A), Cardiovascular Protection (Level A), and GI Side Effects (Level A)
Primary citation count	4
Last reviewed	2026-06-01

Related Guides

How to Cite This Page

ExaminePeptides. "Semaglutide Legal Status: Approval, Research Use, and Regulatory Notes." Last reviewed 2026-06-01. https://examinepeptides.com/answers/semaglutide-legal-status/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.